{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ISL&page=2",
    "query": {
      "intervention": "ISL",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ISL&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-12T22:02:20.854Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06338475",
      "title": "A Biobehavioral Intervention for Latino/Hispanic Young Adults with Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "Goal-Focused Emotion-Regulation Therapy (GET)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Individual Supportive Listening (ISL)",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of California, Irvine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "39 Years",
        "sex": "MALE",
        "summary": "18 Years to 39 Years · Male only"
      },
      "enrollment_count": 100,
      "start_date": "2024-06-01",
      "completion_date": "2026-06",
      "has_results": false,
      "last_update_posted_date": "2025-03-25",
      "last_synced_at": "2026-09-12T22:02:20.854Z",
      "location_count": 1,
      "location_summary": "Irvine, California",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06338475"
    },
    {
      "nct_id": "NCT04248907",
      "title": "Transtibial Pin Lock Suspension at Varying Distraction Values Using a Modified Air Bladder Casting System",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Amputation"
      ],
      "interventions": [
        {
          "name": "0 pound tension",
          "type": "OTHER"
        },
        {
          "name": "2 pound tension",
          "type": "OTHER"
        },
        {
          "name": "4 pound tension",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Loma Linda University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2020-01-28",
      "completion_date": "2020-04-27",
      "has_results": false,
      "last_update_posted_date": "2020-05-01",
      "last_synced_at": "2026-09-12T22:02:20.854Z",
      "location_count": 1,
      "location_summary": "Loma Linda, California",
      "locations": [
        {
          "city": "Loma Linda",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04248907"
    },
    {
      "nct_id": "NCT04644029",
      "title": "Oral ISL QM as PrEP in Cisgender Women at High Risk for HIV-1 Infection (MK-8591-022)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV-I",
        "Human Immunodeficiency Virus Type 1",
        "Prophylaxis"
      ],
      "interventions": [
        {
          "name": "Islatravir",
          "type": "DRUG"
        },
        {
          "name": "Placebo to FTC/TDF",
          "type": "DRUG"
        },
        {
          "name": "FTC/TDF",
          "type": "DRUG"
        },
        {
          "name": "Placebo to ISL",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "16 Years to 45 Years · Female only"
      },
      "enrollment_count": 730,
      "start_date": "2021-02-24",
      "completion_date": "2024-06-11",
      "has_results": true,
      "last_update_posted_date": "2026-02-04",
      "last_synced_at": "2026-09-12T22:02:20.854Z",
      "location_count": 13,
      "location_summary": "Birmingham, Alabama • Washington D.C., District of Columbia • Miami, Florida + 10 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04644029"
    },
    {
      "nct_id": "NCT04652700",
      "title": "Oral Islatravir (MK-8591) Once-Monthly as Preexposure Prophylaxis (PrEP) in Men and Transgender Women Who Are at High Risk for HIV-1 Infection (MK-8591-024)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV Preexposure Prophylaxis"
      ],
      "interventions": [
        {
          "name": "ISL",
          "type": "DRUG"
        },
        {
          "name": "FTC/TDF",
          "type": "DRUG"
        },
        {
          "name": "FTC/TAF",
          "type": "DRUG"
        },
        {
          "name": "Placebo to ISL",
          "type": "DRUG"
        },
        {
          "name": "Placebo to FTC/TDF",
          "type": "DRUG"
        },
        {
          "name": "Placebo to FTC/TAF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "16 Years and older · Male only"
      },
      "enrollment_count": 494,
      "start_date": "2021-03-15",
      "completion_date": "2023-08-04",
      "has_results": true,
      "last_update_posted_date": "2026-05-05",
      "last_synced_at": "2026-09-12T22:02:20.854Z",
      "location_count": 15,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • San Francisco, California + 11 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04652700"
    },
    {
      "nct_id": "NCT04223791",
      "title": "Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV Infection"
      ],
      "interventions": [
        {
          "name": "DOR/ISL",
          "type": "DRUG"
        },
        {
          "name": "BIC/FTC/TAF",
          "type": "DRUG"
        },
        {
          "name": "Placebo to BIC/FTC/TAF",
          "type": "DRUG"
        },
        {
          "name": "Placebo to FDC DOR/ISL",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 643,
      "start_date": "2020-02-18",
      "completion_date": "2025-02-27",
      "has_results": true,
      "last_update_posted_date": "2026-03-27",
      "last_synced_at": "2026-09-12T22:02:20.854Z",
      "location_count": 28,
      "location_summary": "Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 24 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palm Springs",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04223791"
    },
    {
      "nct_id": "NCT06719570",
      "title": "A Study of Doravirine and Islatravir as a Single Entity or Combination Therapy and the Effect of Food in Healthy Adult Participants (MK-8591A-055)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "MK-8591A",
          "type": "DRUG"
        },
        {
          "name": "Islatravir",
          "type": "DRUG"
        },
        {
          "name": "Doravine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "19 Years to 55 Years"
      },
      "enrollment_count": 24,
      "start_date": "2024-01-23",
      "completion_date": "2024-03-15",
      "has_results": false,
      "last_update_posted_date": "2024-12-06",
      "last_synced_at": "2026-09-12T22:02:20.854Z",
      "location_count": 1,
      "location_summary": "Lincoln, Nebraska",
      "locations": [
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06719570"
    },
    {
      "nct_id": "NCT04233216",
      "title": "Doravirine/Islatravir (DOR/ISL) in Heavily Treatment-Experienced (HTE) Participants for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-019)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV-1 Infection"
      ],
      "interventions": [
        {
          "name": "ISL",
          "type": "DRUG"
        },
        {
          "name": "DOR",
          "type": "DRUG"
        },
        {
          "name": "DOR/ISL",
          "type": "DRUG"
        },
        {
          "name": "Placebo to ISL",
          "type": "DRUG"
        },
        {
          "name": "Placebo to DOR",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 35,
      "start_date": "2020-03-18",
      "completion_date": "2023-11-01",
      "has_results": true,
      "last_update_posted_date": "2024-12-27",
      "last_synced_at": "2026-09-12T22:02:20.854Z",
      "location_count": 19,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Palm Springs, California + 15 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palm Springs",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04233216"
    },
    {
      "nct_id": "NCT02233179",
      "title": "The Association Between Unprotected Standing, Walking and Wound Healing in Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Diabetic Foot"
      ],
      "interventions": [
        {
          "name": "Removable cast walker",
          "type": "DEVICE"
        },
        {
          "name": "Irremovable cast walker",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "University of Arizona",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "37 Years",
        "maximum_age": "68 Years",
        "sex": "ALL",
        "summary": "37 Years to 68 Years"
      },
      "enrollment_count": 49,
      "start_date": "2009-06",
      "completion_date": "2012-11",
      "has_results": false,
      "last_update_posted_date": "2014-09-08",
      "last_synced_at": "2026-09-12T22:02:20.854Z",
      "location_count": 1,
      "location_summary": "Tucson, Arizona",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02233179"
    },
    {
      "nct_id": "NCT07266831",
      "title": "A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Human Immunodeficiency Virus Type 1 (HIV-1) Infection"
      ],
      "interventions": [
        {
          "name": "ISL",
          "type": "DRUG"
        },
        {
          "name": "ULO",
          "type": "DRUG"
        },
        {
          "name": "BIC/FTC/TAF",
          "type": "DRUG"
        },
        {
          "name": "Placebo for BIC/FTC/TAF",
          "type": "DRUG"
        },
        {
          "name": "Placebo to ISL/ULO",
          "type": "DRUG"
        },
        {
          "name": "ISL/ULO",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 570,
      "start_date": "2025-12-18",
      "completion_date": "2030-04-03",
      "has_results": false,
      "last_update_posted_date": "2026-09-09",
      "last_synced_at": "2026-09-12T22:02:20.854Z",
      "location_count": 24,
      "location_summary": "Los Angeles, California • Denver, Colorado • Washington D.C., District of Columbia + 20 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Ft. Pierce",
          "state": "Florida"
        },
        {
          "city": "Miami Gardens",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07266831"
    },
    {
      "nct_id": "NCT04515641",
      "title": "Single-Dose Islatravir in Moderate Hepatic Impairment (MK-8591-030)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Human Immunodeficiency Virus (HIV) Infection"
      ],
      "interventions": [
        {
          "name": "Islatravir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 12,
      "start_date": "2020-11-05",
      "completion_date": "2021-09-13",
      "has_results": true,
      "last_update_posted_date": "2025-07-17",
      "last_synced_at": "2026-09-12T22:02:20.854Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04515641"
    }
  ]
}